Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutationsKatherine A Janeway, Su Young Kim, Maya Lodish, et al.
The New England Journal of Medicine|August 16, 2002
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsGeorge D Demetri, Margaret von Mehren, Charles D Blanke, et al.
Nature Communications|March 9, 2017
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationInga-Marie Schaefer, Yuexiang Wang, Cher-Wei Liang, et al.
British Journal of Cancer|September 29, 2022
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GISTInga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in LeiomyosarcomaAdrian Marino-Enriquez, Jan Philipp Novotny, Doga C Gulhan, et al.
Iscience|February 23, 2023
Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosisMiriam Magallón-Lorenz, Ernest Terribas, Sara Ortega-Bertran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2024
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor EscapeThomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, et al.
Cancer Discovery|July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral MimicryAmish J Patel, Sarah Warda, Jesper L V Maag, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 7, 2012
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcomaCheng-Han Lee, Wen-Bin Ou, Adrian Mariño-Enriquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutationsKatherine A Janeway, Su Young Kim, Maya Lodish, et al.
The New England Journal of Medicine|August 16, 2002
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsGeorge D Demetri, Margaret von Mehren, Charles D Blanke, et al.
Nature Communications|March 9, 2017
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationInga-Marie Schaefer, Yuexiang Wang, Cher-Wei Liang, et al.
British Journal of Cancer|September 29, 2022
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GISTInga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in LeiomyosarcomaAdrian Marino-Enriquez, Jan Philipp Novotny, Doga C Gulhan, et al.
Iscience|February 23, 2023
Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosisMiriam Magallón-Lorenz, Ernest Terribas, Sara Ortega-Bertran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2024
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor EscapeThomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, et al.
Cancer Discovery|July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral MimicryAmish J Patel, Sarah Warda, Jesper L V Maag, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 7, 2012
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcomaCheng-Han Lee, Wen-Bin Ou, Adrian Mariño-Enriquez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Pageof 21